New drug tested to stop dangerous transplant complication
NCT ID NCT02867384
Summary
This study tested whether a drug called obinutuzumab could prevent chronic Graft-vs-Host Disease (cGVHD) in patients who received a stem cell transplant. cGVHD is a serious condition where the donor's immune cells attack the recipient's body. In this trial, 181 adult transplant patients were randomly assigned to receive either obinutuzumab or a placebo to see if the drug reduced the need for steroid treatment for cGVHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford University
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.